2024
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. DOI: 10.1016/j.bneo.2024.100049.Peer-Reviewed Original ResearchCyclin-dependent kinase 7Progression-free survivalMultiple myelomaAnalysis of RNA-seq dataMM cellsTherapeutic strategiesPatients treated with venetoclaxCDK7 inhibitor THZ1Overcome venetoclax resistanceRNA-seq dataSix-gene signaturePredictors of responseChromosome 1q gainPersonalized therapeutic strategiesDevelopment of personalized therapeutic strategiesInduce cell deathMarkers of sensitivityBCL2 inhibitorsCDK7 inhibitionMCL1 genePrognostic importanceStratify patientsCyclin-dependentMCL1 levelsPatient population
2023
A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.Peer-Reviewed Original ResearchProgression-free survivalArm BPeripheral neuropathyInduction therapyPrimary endpointOverall survivalAutologous stem cell transplantGrade 3/4 peripheral neuropathyRandomized phase 2 studyTransplant-eligible myeloma patientsRandomized phase II studySecondary primary malignanciesTransplant-eligible patientsTransplant-ineligible patientsAdverse event profilePhase 2 studyPhase II studyStem cell transplantWinship Cancer InstituteInhibitor combination therapyStem cell collectionRegular clinical practiceHigh response rateMultiple myeloma studyMedian follow